Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 32371583)

  • 1. FGFR Inhibition Enhances Sensitivity to Radiation in Non-Small Cell Lung Cancer.
    SenthilKumar G; Fisher MM; Skiba JH; Miller MC; Brennan SR; Kaushik S; Bradley ST; Longhurst CA; Buehler D; Nickel KP; Iyer G; Kimple RJ; Baschnagel AM
    Mol Cancer Ther; 2020 Jun; 19(6):1255-1265. PubMed ID: 32371583
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Translating the therapeutic potential of AZD4547 in FGFR1-amplified non-small cell lung cancer through the use of patient-derived tumor xenograft models.
    Zhang J; Zhang L; Su X; Li M; Xie L; Malchers F; Fan S; Yin X; Xu Y; Liu K; Dong Z; Zhu G; Qian Z; Tang L; Schöttle J; Zhan P; Ji Q; Kilgour E; Smith PD; Brooks AN; Thomas RK; Gavine PR
    Clin Cancer Res; 2012 Dec; 18(24):6658-67. PubMed ID: 23082000
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fibroblast Growth Factor Receptors as Targets for Radiosensitization in Head and Neck Squamous Cell Carcinomas.
    Fisher MM; SenthilKumar G; Hu R; Goldstein S; Ong IM; Miller MC; Brennan SR; Kaushik S; Abel L; Nickel KP; Iyer G; Harari PM; Kimple RJ; Baschnagel AM
    Int J Radiat Oncol Biol Phys; 2020 Jul; 107(4):793-803. PubMed ID: 32298810
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interaction between the estrogen receptor and fibroblast growth factor receptor pathways in non-small cell lung cancer.
    Siegfried JM; Farooqui M; Rothenberger NJ; Dacic S; Stabile LP
    Oncotarget; 2017 Apr; 8(15):24063-24076. PubMed ID: 28445992
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A miRNA Panel Predicts Sensitivity of FGFR Inhibitor in Lung Cancer Cell Lines.
    Ren S; Rivard CJ; Yu H; Genova C; Rozenboom L; Gao D; Hinz TK; Rikke BA; Wynes MW; Caldwell C; Agustoni F; Kenichi Suda ; Jiang T; Zhou C; Heasley LE; Hirsch FR
    Clin Lung Cancer; 2018 Sep; 19(5):450-456. PubMed ID: 30146263
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Kinome RNAi Screens Reveal Synergistic Targeting of MTOR and FGFR1 Pathways for Treatment of Lung Cancer and HNSCC.
    Singleton KR; Hinz TK; Kleczko EK; Marek LA; Kwak J; Harp T; Kim J; Tan AC; Heasley LE
    Cancer Res; 2015 Oct; 75(20):4398-406. PubMed ID: 26359452
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combination treatment of prostate cancer with FGF receptor and AKT kinase inhibitors.
    Feng S; Shao L; Castro P; Coleman I; Nelson PS; Smith PD; Davies BR; Ittmann M
    Oncotarget; 2017 Jan; 8(4):6179-6192. PubMed ID: 28008155
    [TBL] [Abstract][Full Text] [Related]  

  • 8. SWOG S1400D (NCT02965378), a Phase II Study of the Fibroblast Growth Factor Receptor Inhibitor AZD4547 in Previously Treated Patients With Fibroblast Growth Factor Pathway-Activated Stage IV Squamous Cell Lung Cancer (Lung-MAP Substudy).
    Aggarwal C; Redman MW; Lara PN; Borghaei H; Hoffman P; Bradley JD; Newman AJ; Feldman MJ; Minichiello K; Miao J; Mack PC; Papadimitrakopoulou VA; Herbst RS; Kelly K; Gandara DR
    J Thorac Oncol; 2019 Oct; 14(10):1847-1852. PubMed ID: 31195180
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antitumor Effects and Mechanisms of AZD4547 on FGFR2-Deregulated Endometrial Cancer Cells.
    Kwak Y; Cho H; Hur W; Sim T
    Mol Cancer Ther; 2015 Oct; 14(10):2292-302. PubMed ID: 26294741
    [TBL] [Abstract][Full Text] [Related]  

  • 10. FGFR inhibitor AZD4547 can enhance sensitivity of esophageal squamous cell carcinoma cells with epithelial‑mesenchymal transition to gefitinib.
    Luo H; Quan J; Xiao H; Luo J; Zhang Q; Pi G; Ye Y; He R; Liu Y; Su X; Zhao L; Wang G
    Oncol Rep; 2018 May; 39(5):2270-2278. PubMed ID: 29517107
    [TBL] [Abstract][Full Text] [Related]  

  • 11. FGFR1 Is a Potential Prognostic Biomarker and Therapeutic Target in Head and Neck Squamous Cell Carcinoma.
    Koole K; Brunen D; van Kempen PM; Noorlag R; de Bree R; Lieftink C; van Es RJ; Bernards R; Willems SM
    Clin Cancer Res; 2016 Aug; 22(15):3884-93. PubMed ID: 26936917
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The FGFR Family Inhibitor AZD4547 Exerts an Antitumor Effect in Ovarian Cancer Cells.
    Na YR; Kim JY; Song CH; Kim M; Do YT; Vo TTL; Choi E; Ha E; Seo JH; Shin SJ
    Int J Mol Sci; 2021 Oct; 22(19):. PubMed ID: 34639155
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mogrol-mediated enhancement of radiotherapy sensitivity in non-small cell lung cancer: a mechanistic study.
    Yin Z; Zhang X; Sun X; Huo Y; Ji N; Chen K
    Am J Physiol Cell Physiol; 2024 Jun; 326(6):C1753-C1768. PubMed ID: 38682239
    [TBL] [Abstract][Full Text] [Related]  

  • 14. AZD4547: an orally bioavailable, potent, and selective inhibitor of the fibroblast growth factor receptor tyrosine kinase family.
    Gavine PR; Mooney L; Kilgour E; Thomas AP; Al-Kadhimi K; Beck S; Rooney C; Coleman T; Baker D; Mellor MJ; Brooks AN; Klinowska T
    Cancer Res; 2012 Apr; 72(8):2045-56. PubMed ID: 22369928
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CRISPR-Mediated Kinome Editing Prioritizes a Synergistic Combination Therapy for
    Yang Z; Liang SQ; Yang H; Xu D; Bruggmann R; Gao Y; Deng H; Berezowska S; Hall SRR; Marti TM; Kocher GJ; Zhou Q; Schmid RA; Peng RW
    Cancer Res; 2021 Jun; 81(11):3121-3133. PubMed ID: 33685992
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The FGFR1 V561M Gatekeeper Mutation Drives AZD4547 Resistance through STAT3 Activation and EMT.
    Ryan MR; Sohl CD; Luo B; Anderson KS
    Mol Cancer Res; 2019 Feb; 17(2):532-543. PubMed ID: 30257990
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Exogenous Restoration of TUSC2 Expression Induces Responsiveness to Erlotinib in Wildtype Epidermal Growth Factor Receptor (EGFR) Lung Cancer Cells through Context Specific Pathways Resulting in Enhanced Therapeutic Efficacy.
    Dai B; Yan S; Lara-Guerra H; Kawashima H; Sakai R; Jayachandran G; Majidi M; Mehran R; Wang J; Bekele BN; Baladandayuthapani V; Yoo SY; Wang Y; Ying J; Meng F; Ji L; Roth JA
    PLoS One; 2015; 10(6):e0123967. PubMed ID: 26053020
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Radiosensitizing effect of YM155, a novel small-molecule survivin suppressant, in non-small cell lung cancer cell lines.
    Iwasa T; Okamoto I; Suzuki M; Nakahara T; Yamanaka K; Hatashita E; Yamada Y; Fukuoka M; Ono K; Nakagawa K
    Clin Cancer Res; 2008 Oct; 14(20):6496-504. PubMed ID: 18927289
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Co-active receptor tyrosine kinases mitigate the effect of FGFR inhibitors in FGFR1-amplified lung cancers with low FGFR1 protein expression.
    Kotani H; Ebi H; Kitai H; Nanjo S; Kita K; Huynh TG; Ooi A; Faber AC; Mino-Kenudson M; Yano S
    Oncogene; 2016 Jul; 35(27):3587-97. PubMed ID: 26549034
    [TBL] [Abstract][Full Text] [Related]  

  • 20. FGFR2 gene amplification in gastric cancer predicts sensitivity to the selective FGFR inhibitor AZD4547.
    Xie L; Su X; Zhang L; Yin X; Tang L; Zhang X; Xu Y; Gao Z; Liu K; Zhou M; Gao B; Shen D; Zhang L; Ji J; Gavine PR; Zhang J; Kilgour E; Zhang X; Ji Q
    Clin Cancer Res; 2013 May; 19(9):2572-83. PubMed ID: 23493349
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.